1. Αποθετήριο Παραδοτέων Υποτρόφων Δράσεων ΕΣΠΑ Τριτοβάθμιας Εκπαίδευσης 2017-2023
2. Όλο το Αποθετήριο
3. Ερευνητικές ομάδες

Τύπος:	Αναρτημένη ανακοίνωση (poster)
Τίτλος:	The clinical utility of a plasma miRNA signature in multiple myeloma bone disease
Συγγραφέας:	[EL] Τσιακανίκας, Παναγιώτης-Ιωάννης[EN] Tsiakanikas, Panagiotis-Ioannis [EL] Κοντός, Χρήστος[EN] Kontos, Christos [EL] Μαλανδράκης, Παναγιώτης[EN] Malandrakis, Panagiotis [EL] Λιάκου Χριστίνα-Ήβη[EN] Liacos, Christine Ivy [EL] Ντάνασης-Σταθόπουλος, Ιωάννης[EN] Ntanasis-Stathopoulos, Ioannis [EL] Κανέλλιας, Νικόλαος[EN] Kanellias, Nikolaos [EL] Γαβριατοπούλου, Μαρία[EN] Gavriatopoulou, Maria [EL] Καστρίτης, Ευστάθιος[EN] Kastritis, Efstathios [EL] Αυγέρης, Μαργαρίτης[EN] Avgeris, Margaritis [EL] Δημόπουλος, Αθανάσιος - Μελέτιος[EN] Dimopoulos, Meletios Athanasios [EL] Σκορίλας, Ανδρέας[EN] Scorilas, Andreas
Μέλος ερευνητικής ομάδας:	[EL] Παπανώτα, Αριστέα-Μαρία[EN] Papanota, Aristea-Maria
Επικεφαλής ερευνητικής ομάδας:	[EL] Τέρπος, Ευάγγελος[EN] Terpos, Evangelos
Ημερομηνία:	Ιου-2021
Περίληψη:	Background: Multiple myeloma bone disease (MMBD) affects approximately 80% of newly diagnosed multiple myeloma (MM) patients and is associated with poor quality of life and worse survival. The pathophysiology of MMBD is complex and results from deregulation of bone remodeling. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at post-transcriptional and/or translational level. miRNAs are implicated in the regulation of key physiological processes, including bone remodeling. However, little is known about their implication in MMBD. Aim: The purpose of the current study was the evaluation of an established panel of 19 miRNAs associated with bone disease in osteoporosis of different etiology, in MMBD. Methods: Small RNAs were isolated from blood plasma samples of 64 newly diagnosed MM cases, i.e. 37 patients with and 27 without osteolytic lesions, assessed via whole-body low-dose computed tomography. After RNA polyadenylation and first-strand cDNA synthesis, 19 miRNAs (let-7b-5p, miR-17-5p, miR-19b-3p, miR-29b-3p, miR-31-5p, miR-127-3p, miR-133b, miR-141-3p, miR-143-3p, miR-144-5p, miR-152-3p, miR-188-5p, miR-203a, miR-214-3p, miR-320a, miR-335-5p, miR-375, miR-550a-3p, miR-582-5p) were quantified by means of real-time qPCR, using LNA-enhanced forward and reverse primers as well as miGreen for detection. Spike-in control RNAs were used for normalization of miRNA levels. Last, biostatistical analysis was performed. Results: Significantly lower levels of miR-143-3p (p=0.022), miR-17-5p (p=0.023), miR-214-3p (p=0.003), and miR-335-5p (p=0.018) were observed in MM patients with osteolytic lesions, compared to MM patients without osteolytic lesions. Receiver operating characteristic (ROC) curve analysis showed that each of the aforementioned miRNAs can accurately distinguish MM patients with MMBD from MM patients without MMBD: miR-17-5p (AUC=0.67; p=0.023), miR-143-3p (AUC=0.68; p=0.022), miR-214-3p (AUC=0.74; p=0.003), and miR-335-5p (AUC=0.69; p=0.018). In order to obtain a miRNA signature with higher discriminatory ability regarding MMBD, we built multivariate logistic regression models combining the levels of multiple miRNAs, selected among miR-17-5p, miR-143-3p, miR-214-3p, and miR-335-5p. The best predictive model resulted from the combination of these 4 miRNAs (function: F=0.66 x log(miR-335-5p) – 0.90 x log(miR-17-5p) – 0.44 x log(miR-143-3p) –1.67 x log(miR-143-3p) + 5.378. The evaluation of the proposed model using ROC analysis showed its significantly increased performance to successfully detect the presence of osteolytic bone disease in MM patients (AUC=0.80; p=0.001). Furthermore, a cutoff value of Fc=0.40, corresponds to increased diagnostic sensitivity of the described model (sensitivity: 96%, specificity: 53%), while a cutoff value of Fc=0.77 corresponds to increased diagnostic specificity (sensitivity: 48%, specificity: 94%). Conclusion: Our study proposes a diagnostic model consisting of 4 miRNAs (miR-17-5p, miR-143-3p, miR-214-3p, and miR-335-5p) which and predict the occurrence of osteolytic lesions in MM patients. The suggested miRNA signature could be a useful tool able to guide therapeutic decision making, especially in ambiguous cases. Acknowledgement: This research is co-financed by Greece and the European Union (European Social Fund - ESF) through the Operational Programme «Human Resources Development, Education and Lifelong Learning 2014-2020» in the context of the project “Study of the expression of small non-coding RNAs in multiple myeloma and their correlation with bone disease.”(MIS 5047940).
Γλώσσα:	Αγγλικά
Τόπος δημοσίευσης:	Virtually
Σελίδες:	1
DOI:	10.1097/HS9.0000000000000566
Θεματική κατηγορία:	[EL] Ιατρική έρευνα και Πειραματική ιατρική[EN] Research and Experimental medicine
Λέξεις-κλειδιά:	microRNA signature; molecular biomarkers; osteolytic lesions; MMBD
Κάτοχος πνευματικών δικαιωμάτων:	© 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Ηλεκτρονική διεύθυνση του τεκμηρίου στον εκδότη:	https://journals.lww.com/hemasphere/Citation/2021/06002/EHA2021_Virtual_Congress_Abstract_Book.1.aspx
Ηλεκτρονική διεύθυνση περιοδικού:	https://journals.lww.com/hemasphere/pages/default.aspx
Τίτλος πηγής δημοσίευσης:	HemaSphere: Abstract Book EHA2021 Virtual Congress
Τεύχος:	S2
Τόμος:	5
Σελίδες τεκμηρίου (στην πηγή):	448-449
Όνομα εκδήλωσης:	EHA2021 Virtual Congress Connecting Hematology For Clinical and Research Excellence
Τοποθεσία εκδήλωσης:	Virtual Conference
Ημ/νία έναρξης εκδήλωσης:	09/06/2021
Ημ/νία λήξης εκδήλωσης:	17/06/2021
Σημειώσεις:	This research is co-financed by Greece and the European Union (European Social Fund - ESF) through the Operational Programme «Human Resources Development, Education and Lifelong Learning 2014-2020» in the context of the project “Study of the expression of small non-coding RNAs in multiple myeloma and their correlation with bone disease.”(MIS 5047940).
Εμφανίζεται στις συλλογές:	Ερευνητικές ομάδες